# Benzopyran, benzothiapyran and quinoline compounds and pharmaceutical compositions containing them.

## Abstract
These are described compounds of formula I, CHEM in which X is O , S or NR3 , R3 is hydrogen or alkyl C 1 to 6, A is COOH or 5 1H tetrazolyl , and B is hydrogen, or A and B together form a chain N N NH , R1 is hydrogen or hydroxy, R2 is hydroxy or esterified hydroxy, R6 is hydrogen or alkyl C 1 to 3, R7 is hydrogen or methyl, and R8 is alkyl C 1 to 4 optionally substituted by phenyl, provided that when B is hydrogen, A is COOH, X is O , R1 is hydrogen, R2 is hydroxy, R6 and R7 are both hydrogen then R8 is not propyl, and pharmaceutically acceptable derivatives thereof. There are also described methods for making the compounds and pharmaceutical, e.g gastric acid secretion inhibiting, compositions containing them.

## Claims
What we claim is 1. A compound of formula I,EMI56.1 in which X is O , S or NR3 , R3 is hydrogen or alkyl C 1 to 6, A is COOH or 5 lH tetrazolyl , and B is hydrogen, or A and B together form a chain N N NH , R1 is hydrogen or hydroxy, R2 is hydroxy or esterified hydroxy, R6 is hydrogen or alkyl C 1 to 3, R7 is hydrogen or methyl, and R8 is alkyl C 1 to 4 optionally substituted by phenyl, provided that when B is hydrogen, A is COOH, X is O , R1 is hydrogen, R2 is hydroxy, R6 and R7 are both hydrogen then R8 is not propyl, and pharmaceutically acceptable derivatives thereof. 2. A compound according to Claim 1, wherein B is hydrogen and A is COOH. 3. A compound according to Claim 1 or 2, wherein X is S or O . 4. A compound according to any one of the preceding claims, wherein R1 is hydrogen. 5. A compound according to any one of the preceding claims, wherein R2 is hydroxy esterified by a C 1 to 7 hindered monocarboxylic acid, with an aryl C7 to 12 acid, or with a C3 to 7 dibasic acid. 6. A compound according to Claim 5, wherein R2 is hydroxy esterified by benzoic acid. 7. A compound according to any one of the preceding claims, wherein R6 is hydrogen, ethyl or propyl, R7 is hydrogen and R8 is ethyl, propyl, butyl or benzyl. 8. 5 5 2 Hydroxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 yl lH tetrazole, l Ethyl 1,4 dihydro 5 2 hydroxypropoxy 4 oxo 8propylquinoline 2 carboxylic acid, 1,4 Dihydro 5 2 hydroxypropoxy 4 oxo 8 propylquinoline 2 carboxylic acid, 5 2 Hydroxypropoxy . 4 oxo 6, 8 dipropyl 4H l benzopyran 2 carboxylic acid, 5 2 Hydroxypropoxy 7 methyl 4 oxo 8 propyl 4H l benzopyran 2 carboxylic acid, 6, 8 Diethyl 5 2 hydroxypropoxy 4 oxo 4H l benzopyran 2 carboxylic acid, 5 2,3 Dihydroxy n propoxy 4 oxo 8 n propyl 4H lbenzopyran 2 carboxylic acid, 5 2 Hydroxypropoxy 4 oxo 8 phenylmethyl 4H l benzopyran 2 carboxylic acid, 5 2 BenzOyloxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 carboxylic acid, Butanedioic acid, mono 2 ethoxycarbonyl 4 oxo 8 propyl 4H 1 benzopyran 5 yloxy prop 2 yl ester 5 2 Hydroxypropoxy 4 oxo 8 propyl 4H thiabenzopyran 2 carboxylic acid, 8 1, 1 Dimethylethyl 5 2 hydroxypropoxy 4 oxo 4H lJ benzopyran 2 carboxylic acid 8 2 Hydroxypropoxy 9 oxo 5 propyl lH,9H benzopyrano r2,3 d v triazole, or the sodium salt of any one thereof. 9. A pharmaceutical composition conprising a compound according to any one of the preceding claims and a pharmaceutically acceptable adjuvant, diluent or carrier. 10. A process for the production of a compound of formulaI, or a pharmaceutically acceptable derivative thereof, which comprises a producing a compound of formula I in which A and B together form a chain N N NH by removing a protecting group L from a compound of formula III, EMI59.1 in which X, R1, R2, R6, R7 and R8 are as defined above, and L is a protecting group, b producing a compound of formula I in which B is hydrogen and A is 5 lH tetrazolyl , by reacting a compound of formula IV,EMI59.2 in which X, R1, R2, R6, R7 and R8 are as defined above, with an azide, in solvent which is inert under the reaction conditions, c producing a compound of formula I in which R1 or R2 is hydroxy by selectively reducing a compound of formula V, EMI60.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, and R5 represents a group CH2CZCEZ, where one Z represents carbonyl oxygen and the other represents H2, with a suitable selective carbonyl reducing agent, d producing a compound of formula I in which B is hydrogen and A is COOH by hydrolysing a compound of formulaVI,EMI60.2 in which D represents a group hydrolyseable to COOH, and X, R1, R2, N , R7 and R8 are as defined above, e producing a compound of formula I in which B is hydrogen and A is COOH by cyclising a compound of formulaVII, EMI61.1 in which R1, R2, R6, R7 and R8 are as defined above, A1 and A2 represent the pairs of groups i COCH2COCOR and OM, or ii H and X C COR CH COR X is as defined above, RW represents OM, or a group which is hydrolysable thereto, and M represents hydrogen or a cation, and if necessary or desired hydrolysing the group COR , to a group COOM, f reacting a compound of formula VIII,EMI61.2 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, with propylene oxide or a compound of formula IX, R1CE2CHR2CH2G IX in which G is a good leaving group, g producing a compound of formula I in which R1 andR2 are both hydroxy by i hydrolysing a compound of formula X,EMI62.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, or ii subjecting a compound of formula XI,EMI62.2 in which X, A, B, R6, R7 and R8 are as defined above, or a salt, ester or amide thereof, to mammalian metabolism, or iii reaction of a compound of formula XII,EMI63.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, with osmium tetroxide, and hydrolysis of the resulting complex, or h producing a compound of formula I in which R2 is esterified hydroxy, by reaction of a corresponding compound of formula I, or a salt, carboxylic ester or amide thereof, in which R2 is hydroxy with an appropriate acid, or a derivative thereof, and where desired or necessary converting the resulting compound of formula I to a pharmaceutically acceptable derivative thereof, or vice versa. 11. A compound according to any one of Claims 1 to 9 for use as a pharmaceutical. What we claim is 1. A process for the production of a compound of formulaI,EMI64.1 in which X is O , S or NR3 , R3 is hydrogen or alkyl C 1 to 6, A is COOH or 5 lH tetrazolyl , and B is hydrogen, or A and B together form a chain N N NH , R1 is hydrogen or hydroxy, R2 is hydroxy or esterified hydroxy, R6 is hydrogen or alkyl C 1 to 3, R7 is hydrogen or methyl, and R8 is alkyl C 1 to 4 optionally substituted by phenyl, provided that when B is hydrogen, A is COOH, X is O , R1 is hydrogen, R2 is hydroxy, R6 and R7 are both hydrogen then R8 is not propyl, or a pharmaceutically acceptable derivative thereof, which comprises a producing a compound of formula I in which A and B together form a chain N N NH by removing a protecting group L from a compound of formula III,EMI65.1 in which X, R1, R2, R6, R7 and R8 are as defined above, and L is a,protecting group, b producing a compound of formula I in which B is hydrogen and A is 5 lH tetrazolyl , by reacting a compound of formula IV,EMI65.2 in which X, R1, R2 R6, R7 and R8 are as defined above, with an azide, in solvent which is inert under the reaction conditions, c producing a compound of formula I in which R1 or R2 is hydroxy by selectively reducing a compound of formula V,EMI66.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, and R5 represents a group CH2CZCHZ, where one Z represents carbonyl oxygen and the other represents H2, with a suitable selective carbonyl reducing agent, d producing a compound of formula I in which B is hydrogen and A is COOH by hydrolysing a compound of formulaVI,EMI66.2 in which D represents a group hydrolyseable to COOH, and X, R1, R2, R6, R7 and R8 are as defined above, e producing a compound of formula I in which B is hydrogen and A is COOH by cyclising a compound of formulaEMI67.1 in which R1, R2, R6, R7 and R8 are as defined above, A1 and 2 represent the pairs A2 represent the pairs of groups i COCH2COCOR and OM, or ii H and X C COR CH COR X is as defined above, R represents OM, or a group which is hydrolysable thereto, and M represents hydrogen or a cation, and if necessary or desired hydrolysing the group COR , to a group COOM, f reacting a compound of formula VIII,EMI67.2 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, with propylene oxide or a compound of formula IX, R1CH2CHR2CH2G IX in which G is a good leaving group, g producing a compound of formula I in which R1 andR2 are both hydroxy by i hydrolysing a compound of formula X,EMI68.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, or ii subjecting a compound of formula XI,EMI68.2 in which X, A, B, R6, R7 and R8 are as defined above, or a salt, ester or amide thereof, to mammalian metabolism, or iii reaction of a compound of formula XII,EMI69.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, with osmium tetroxide, and hydrolysis of the resulting complex, or h producing a compound of formula I in which R2 is esterified hydroxy, by reaction of a corresponding compound of formula I, or a salt, carboxylic ester or amide thereof, in which R2 is hydroxy with an appropriate acid, or a derivative thereof, and where desired or necessary converting the resulting compound of formula I to a pharmaceutically acceptable derivative thereof, or vice versa. 2. A process according to Claim 1, wherein B is hydrogen and A is COOR. 3. A process according to Claim 1 or 2, wherein X is Sor O . 4. A process according to any one of the preceding claims, wherein R1 is hydrogen. 5. A process according to any one of the preceding claims, wherein R2 is hydroxy esterified by a C I to 7 hindered monocarboxylic acid, with an aryl C7 to 12 acid, or with a C3 to 7 dibasic acid. 6. A process according to Claim 5, wherein R2 is hydroxy esterified by benzoic acid. 7. A process according to any one of the preceding claims, wherein .R6 is hydrogen, ethyl or propyl, R7 is hydrogen and R8 is ethyl, propyl, butyl or benzyl. 8. A process according to Claim 1, wherein the compound of formula I is 5 r 5 2 Hydroxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 ylllH tetrazole, l Ethyl 1,4 dihydro 5 2 hydroxypropoxy 4 oxo 8propylquinoline 2 carboxylic acid, 1,4 Dihydro 5 2 hydroxypropoxy 4 oxo 8 propyltuinoline 2 carboxylic acid, 5 2 Hydroxypropoxy 4 oxo 6 , 8 dipropyl 4H l benzopyran 2 carboxylic acid, 5 2 Hydroxypropoxy 7 methyl 4 oxo 8 propyl 4H l benzopyran 2 carboxylic acid, 6,8 Diethyl 5 2 hydroxypropoxy 4 oxo 4H l benzopyran 2 carboxylic acid, 5 2,3 Dihydroxy n propoxy 4 oxo 8 n propyl 4H lbenzopyran 2 carboxylic acid, 5 2 Hydroxypropoxy 4 oxo 8 phenylmethyl 4H l benzopyran 2 carboxylic acid, 5 2 Benzoyloxypropoxy 4 oxo 8 propyl 4H 1 benzopyran 2 carboxylic acid, Butanedioic acid, mono 2. ethoxyearbonyl 4 oxo 8 propyl 4H l benzopyran 5 yloxy prop 2 yl ester 5 2 Hydroxypropoxy 4 oxo 8 propyl 4H l thiabenzopyran 2 carboxylic acid 8 1,1 Dimethyiethyl 5 2 hydroxypropoxy 4 oXo 4Htllbenzopyran 2 carboxylic acid 8 2 Hydroxypropoxy 9 oxo 5 propyl lH,9H benzopyrano t2,3 d v triazole, or the sodium salt of any one thereof.

## Description
BENZOPYRAN BENZOTHIAPYRAN AND QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING ThEM This invention relates to new compounds, methods for their preparation and pharmaceutical compositions containing them. A large number of monochromone 2 carboxylic acids are known as anti allergic agents, and a small number of these compounds, in particular the compound described in BritishPatent Specification No 1,488,707, have been disclosed as having the ability to inhibit gastric acid secretion. We have now found that a selected group of compounds have advantageous properties as disclosed herein. According to the invention we provide compounds of formula I,EMI1.1 in which X is O , S or NR3 R3 is hydrogen or alkyl C 1 to 6,A is COOH or 5 lH tetrazolyl , and B is hydrogen, or A and B together form a chain N N NH ,R1 is hydrogen or hydroxy, R2 is hydroxy or esterified hydroxy, R6 is hydrogen or alkyl C 1 to 3, R7 is hydrogen or methyl, and R8 is alkyl C 1 to 4 optionally substituted by phenyl, provided that when B is hydrogen, A is COOs, X is O , R1 is hydrogen, R2 is hydroxy, R6 and b are both hydrogen then R8 is not propyl, and pharmaceutically acceptable derivatives thereof. According to our invention we also provide a process for the preparation of a compound of formula I, or a pharmaceutically acceptable derivative thereof, which comprises a producing a compound of formula I in which A and B together form a chain N N NH by removing a protecting group L from a compound of formula III,EMI2.1 in which X, R1, R2, R6, R7 and R8 are as defined above, and L is a protecting group, b producing a compound of formula I in which B is hydrogen and A is 5 1H tetrazolyl , by reacting a compound of formula IV,EMI3.1 in which X, R1, R2, R6, R7 and R8 are as defined above, with an. azide, in solvent which is inert under the reaction conditions, c producing a compound of formula I in which R1 orR2 is hydroxy by selectively reducing a compound of formula V,EMI3.2 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, and R5 represents a group CH2CZCHZ, where one Z represents carbonyl oxygen and the other represents H2, with a suitable selective carbonyl reducing agent, d producing a compound of formula I in which B is hydrogen and A is COOH by hydrolysing a compound of formula VI,EMI4.1 in which D represents a group hydrolyseable to COOH, and X, R1, R6, R7 and R8 are as defined above, e producing a compound of formula I in which B is hydrogen and A is COOH by cyclising a compound of formulaVII,EMI4.2 in which R1, R2, R6, R7 and R8 are as defined above, A1 and A2 A1 and A2 represent the pairs of groups i COCH2COCOR and OM, or ii H and X C COR CH COR X is as defined above, R represents OM, or a group which is hydrolysable thereto, and M represents hydrogen or a cation, and if necessary or desired hydrolysing the group COR , to a group COOM, f reacting a compound of formula VIII,EMI5.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, with propylene oxide or a compound of formula.IX, R1CH2CHR2CH2G IX in which G is a good leaving group, g producing a compound of formula I in which R1 andR2 are both hydroxy by i hydrolysing a compound of formula X,EMI6.1 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, or ii subjecting a compound of formula XI,EMI6.2 in which X, A, B, R6, R7 and R8 are as defined above, or a salt, ester or amide thereof, to mammalian metabolism, or iii reaction of a compound of formula XII,EMI6.3 or a salt, ester or amide thereof, in which X, A, B, R6, R7 and R8 are as defined above, with osmium tetroxide, and hydrolysis of the resulting complex, or h producing a compound of formula I in which R2 is esterified hydroxy, by reaction of a corresponding compound of formula I, or a salt, carboxylic ester or amide thereof, in which R2 is hydroxy with an appropriate acid, or a derivative thereof, and where desired or necessary converting the resulting compound of formula I to a pharmaceutically acceptable derivative thereof, or vice versa. In process a L may be an N protecting group removable by acidolysis with a strong acid. Suitable examples of L include labile benzyl groups or triphenylmethyl. Examples of labile benzyl groups include benzyl substituted in the phenyl ring by one or more C 1 4 alkoxy groups, for example 4 methoxy , 2,4 dimethoxy or 2,4,6 trimethoxybenzyl. A particularly suitable example of L is 4 methoxybenzyl. Suitable acids include trifluoroacetic and methanesuiphonic acids. The reaction may be carried out at a temperature of from 25 to 150 0C, preferably 50 to 7O0C. LI may also be an N protecting group removable by hydrogenolysis. Examples of such groups include l phenylalkyl groups, particularly benzyl. The hydrogenolysis may conveniently be carried out using conventional techniques known per se. Suitable solvents which are inert under the reaction conditions of process b include those in which both the reagents are soluble, e.g. N,N dimethylformamide, dimethylsulphoxide, tetrahydrofuran, diethyl glycol and ethyl methyl glycol. The reaction is preferably carried out at a temperature of from about 200 to 1300C, The azide used in the reaction is preferably ammonium or an alkali metal azide, e.g. sodium or lithium azide. The reaction may, if desired, be carried out in the presence of an electron acceptor, e.g. aluminium chloride, boron trifluoride, ethyl sulphonic acid or benzene sulphonic acid. Alternatively the reaction may be carried out using hydrazoic acid under greater than atmospheric pressure.When an azide other than hydrazoic acid is used, e.g.sodium azide, the product of the reaction will be the corresponding tetrazole salt. This salt m√Öay readily be converted to the free acid by treatment with strong acid, e.g. hydrochloric acid. Suitable selective carbonyl reducing agents in process c include potassium or sodium borohydride, or aluminium isopropoxide. The reduction may be carried out in a solvent which is inert under the reaction conditions, e.g. ethanol or dioxan, at a temperature of from about 5 to 750C. In process d , the group D may be, for example, an ester, preferably a lower alkyl ester, e.g. methyl or ethyl an acid halide, e.g. chloride an amide, e.g. CONRxRy, where one or both of Rx and Ry represent hydrogen, or lower alkyl, e.g. methyl or ethyl or a nitrile group, which may be hydrolysed to a COOH group. The hydrolysis may be carried out using acid conditions, for example, using a hydrogen halide, e.g. hydrogen bromide or hydrogen chloride in acetic acid, or a mixture of aqueous dioxan and hydrochloric acid, or under mildly basic conditions, e.g. using sodium hydroxide, sodium carbonate or sodium bicarbonate, in a suitable solvent, inert to the reaction conditions, for example a lower alcohol, e.g. ethanol or methanol. The hydrolysis may be carried out at a temperature of from about 5 to 1200C, depending on the compounds used. The cyclisation of process e i may be carried out by heating, or under basic or neutral conditions. It is however preferred to carry out the cyclisation in the presence of an acid, e.g. hydrochloric acid, and in a solvent which is inert under the reaction conditions, e.g.ethanol. The reaction may be carried out at from about 200 to 150 0C. The group COR is preferably an ester group, e.g. R may be a lower alkoxy group. When M is a cation it may be, for example, an alkali metal cation. The cyclisation of process e ii may be carried out by treating the compound of formula VII with a cyclising agent, for example a dehydrating agent such as chlorosulphonic, polyphosphoric or sulphuric acid. The reaction is preferably carried out under anhydrous conditions and may be carried out at a temperature of from about 0 to 1000C. Alternatively, cyclisation may be achieved by converting the free carboxy groups of the compound of formula VII to acyl halide groups and subjecting the resulting acyl halide to an intramolecularFriedel Crafts reaction. As a further alternative, particularly when X is NR3 , the cyclisation may be carried out by heating, e.g. to a temperature of 200 to 3000C, with or without a solvent. In process f the good leaving group G may be, for example, an anion forming group, e.g. a chlorine, bromine or iodine atom or an alkane sulphonate group. The reaction is preferably carried out in a solvent which is inert under the reaction conditions, e.g.dimethylformamide, and in the presence of a strong base, e.g. sodium hydride. The reaction is preferably carried out at a temperature of from about 25 to 1500C. The reaction involving propylene oxide may be carried out without a solvent or in a solvent which is inert under the reaction conditions, e.g., dimethylformamide. The reaction is preferably carried out at a temperature of from about 750 to 1750C in the presence of a base, e.g., sodium hydroxide or thallous ethoxide. The hydrolysis of process g i is preferably carried out in an aqueous medium, e.g. water, and under mildly basic or mildly acidic conditions. The reaction may conveniently be carried out at a temperature of from about 5 to 50 C, e.g. at room temperture. Process g ii may be carried out by administering the starting material to a suitable mammal or mammalian extract. The starting material may conveniently be administered in an aqueous medium, and the desired product may be isolated from the animal s urine, or from the extract, using conventional processes, e.g. high performance liquid chromatography. The reaction of process g iii may be carried out in the presence of hydrogen peroxide, and conveniently is carried out at about room temperature. In process h the esterification may be carried out by reacting the free OH group with a compound RCOG in which G is as described above for process f and may also be O alkanoyl or trifluoroacetyl. The reaction is preferably carried out in the presence of a non nucleophilic proton acceptor, e.g. triethylamine or pyridine. Where the ester is with a dicarboxylic acid the starting material may be reacted with an appropriate anhydride. The reaction may be carried out in a solvent which is inert under the reaction conditions, e.g. a polar aprotic solvent such as 1,4 dioxan, dimethylformamide 6r N methyl pyrrolidone, or a halogenated hydrocarbon, for example dichloromethane or dichloroethane. The reaction may be carried out at a temperature of from about 0 to 1050C. In processes c , f , g and h when an ester starting material is ,used we prefer it to be a C 1 to 6, e.g. an ethyl, ester. The starting materials for the above processes may be made by the processes described in the Examples or by processes analogous thereto or by processes analogous to those described above. Thus the compounds of formula III may be prepared by processes analogous to processes c , f , g i , g iii or h or by conventional processes known per se. The compound of formula IV may be made from the corresponding free acid or from known compounds using conventional techniques known per se, e.g. conversion of the acid to an amide and dehydration of the amide to yield the nitrile. The compounds of formula V may be made by reacting a compound of formula VIII with a reagent R5G in whichR5 and G are as defined above, in the presence of a proton acceptor, e.g. potassium carbonate, in a solvent inert to the reaction conditions, e.g. acetone, at a temperature of from about 5 to 85 C. The compounds of formula V in which R5 represents CE2COCH3 may also be made by reacting the corresponding compound of formula VIII or an ester, amide or salt thereof, with HC CH2G, where G is as defined above e.g. bromine in the presence of a proton acceptor, e.g. potassium carbonate, in a suitable solvent, e.g.acetone, to give an intermediate in which R5 represents CH2 C CH, followed by hydration of the acetylenic bond using water, in the presence of a suitable catalyst, e.g.mercuric chloride or mercuric acetate, in a suitable solvent, e.g. ethanol, containing an acid, e.g.p toluenesulphonic acid. The compounds of formula VI may be made by processes analogous to process c , e , f , g i , g iii or h . The compounds of formulae VII, VIII, IX, X, XI andXII are either known, or may be made from known compounds using conventional methods known per ee. The compounds of formula I and the intermediates therefore may be isolated from their reaction mixtures using conventional techniques. Pharmaceutically acceptable derivatives of the compounds of formula I include pharmaceutically acceptable salts, and, where A is COOH, esters and amides of the 2 carboxylic acid group. Suitable salts include ammonium, alkali metal e.g. sodium, potassium and lithium and alkaline earth metal salts e.g. calcium or magnesium , and salts with suitable organic bases, e.g. salts with hydroxylamine, lower alkyl amines, e.g. hydroxy substituted alkylamines such as tris hydroxymethyl methylamine, or with simple monocyclic nitrogen heterocyclic compounds, e.g. piperidine or morpholine. Suitable esters include simple C 1 to 6 alkyl esters, e.g. the ethyl or butyl ester, esters derived from alcohols containing basic groups, e.g. di lower alkyl amino substituted alkanols such as the 2 diethylamino ethyl ester, and acyloxy alkyl esters, e.g. a lower acyloxy lower alkyl ester such as the pivaloyloxymethyl ester, or a bis ester der ived from a di hydroxy compound, e.g. a di hydroxy lower alkyl ether, e.g. the bis 2 oxapropan 1,3 diyl ester. The esters may be made by conventional techniques, e.g. esterification, transesterification or reaction of the acid, or a salt thereof, with an appropriate compound containing a good leaving group.The amides may be, for example, unsubstituted or mono or di C 1 to 6 alkyl amides and may be made by conventional techniques, e.g. reaction of an ester ofthe corresponding acid with ammonia or an appropriate amine. The compounds of formula I and pharmaceutically acceptable derivatives thereof are useful because they possess pharmacological activity in animals in particular they are useful because they inhibit the release and or action of pharmacological mediators which result from the in vivo combination of certain types of antibody and specific antigen, e.g. the combination of reaginic antibody with specific antigen see Example 27 of BritishPatent Specification No. 1,292,601 . In man, both subjective and objective changes which result from the inhalation of specific antigen by sensitised subjects are inhibited by prior administration of the new compounds.Thus the new compounds are indicated for use in the treatment of asthma, e.g. allergic asthma. The new compounds are also indicated for use in the treatment of so called intrinsic asthma in which no sensitivity to extrinsic antigen can be demonstrated . The new compounds may also be of value in the treatment of other conditions in which antigen antibody reactions are responsible for disease, for example, hay fever certain eye conditions, e.g. trachoma alimentary allergy, e.g. urticaria and atopic eczema and gastrointestinal allergy, especially in children, e.g. milk allergy. The new compounds may also be used for the prevention or inhibition of gastric acid secretion, and or the treatment of conditions normally involving excess gastric acid secretion, e.g. peptic, duodenal, gastric, recurrent or stormal ulceration, dyspepsia, duodenitis, ZollingerEllison syndrome, reflux oesophagitis and the management of haemorrhage, e.g. from erosion or ulcers, in the upper gastrointestinal tract, especially when a major blood vessel is not involved. The compounds may also be used to reduce the chance of haemorrhage in patients with severe hepatic failure who are known to be at special risk. The above conditions may be treated whether or not they are associated with excess gastric acid secretion. For the above mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of from 0.1 to 50 mg per kg of animal body weight in the test set out inExample 27 of the British Patent Specification No.1,292,601. For man the indicated total daily dosage is in the range of from lmg to 3,500mg preferably from lmg to 3,000mg and more preferably from lmg to 600mg, which may be administered in divided doses from 1 to 6 times a day or in sustained release form. Thus unit dosage forms suitable for administration by inhalation or oesophageally comprise from 0.17mg to 600mg, preferably 0.17mg to 500mg and more preferably from 0.17mg to 100mg of the compound preferably admixed with a solid or liquid pharmaceutically acceptable diluent, carrier or adjuvant. The compounds of formula I, and pharmaceutically acceptable derivatives thereof, have the advantage that they are more efficacious in certain pharmacological models, are more readily absorbed, are longer acting, e.g.when inhaled, are more active, have less undesirable side effects or possess other advantageous properties than compounds of similar structure to the compounds of formula I. According to the invention there is also provided a process for the production of a pharmaceutically acceptable salt of a compound of formula I, which comprises treating a compound of formula I or, where A is a COOH group an ester thereof, or another salt thereof, with a compound containing an available pharmaceutically acceptable cation and capable of converting the compound of formula I or the salt or ester thereof, to a pharmaceutically acceptable salt of the acidic function Compounds capable of converting the compound of formula I, or the salt or ester thereof, to a pharmaceutically acceptable salt thereof include compounds, e.g. bases and ion exchange resins, containing pharmaceutically acceptable cations, e.g. sodium, potassium, calcium, ammonium and appropriate nitrogen containing organic cations. In the compounds of formula I we prefer B to be hydrogen and A to be 5 lH tetrazolyl or more preferably COOH. R3 may be hydrogen or alkyl C 1 to 3, e.g.ethyl. We particularly prefer X to be S or O . R is preferably hydrogen. R2 is preferably OH or an ester thereof with a C 1 to 7 hindered mono carboxylic acid, e.g. pivalic acid, or with an aryl C7 to 12 acid, e.g. benzoic acid or with a C3 to 7 dibasic acid, e.g.glutaric or succinic acid. R6 may be, for example, hydrogen, ethyl or propyl. R7 is preferably hydrogen.R8 is preferably ethyl, propyl, butyl or benzyl.According to our invention we also provide a pharmaceutical composition comprising preferably less than 80 , and more preferably less than 50 by weight of a compound of formula I, or a pharmaceutically acceptable derivative thereof, in combination with a pharmaceutically acceptable adjuvant, diluent or carrier. Examples of suitable adjuvants, diluents or carriers are for tablets, capsules and dragees microcrystalline cellulose, calcium phosphate, diatomaceous earth, a sugar such as lactose, dextrose or mannitol, talc, stearic acid, starch, sodium bicarbonate and or gelatin for suppositories, natural or hardened oils 6r waxes and for inhalation compositions, coarse lactose or aerosol propellants.The compound of formula I, or the pharmaceutically acceptable derivative thereof, preferably is in a form having a mass median diameter of from 0.01 to 10 microns. The compositions may also contain suitable preserving, stabilising and wetting agents, solubilizers, sweetening and colouring agents and flavourings. The compositions may, if desired, be formulated in sustained release form. We prefer compositions which are designed to be taken oesophageally and to release their contents in the gastrointestinal tract. Certain of the compounds of formula I exist in optically active forms. The invention also provides the optical isomers of these compounds and mixtures, including racemic mixtures thereof. The compounds may be resolved into their optical isomers using conventional techniques. The invention is illustrated, but in no way limited, by the following Examples in which temperatures are in 0C. Example 1 5 r5 2 Hydroxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 yl lH tetrazole, sodium salt A stirred mixture of 5 2 hydroxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 carbonitrile, 9.lg , ammonium chloride, 2.05g , and sodium azide, 2.55g , in dry dimethylformamide, l00ml , was heated on a steam bath for 3 hours, poured into 3M HC1 and extracted into methylene chloride. The extracts were washed well with water, dried over MgSO4, filtered and evaporated. The residue was dissolved in sodium bicarbonate solution and washed by shaking with ethyl acetate. A solid was precipitated from the aqueous layer. This solid was filtered off, washed with ethyl acetate and with cold water, then dried, leaving the required salt as a pale fawn powder, 4.93g .Elemental Analysis C H N Found 47.8 5.32 13.97 C16H17N4Na04 12.17 H20 Requires 47.878 5.568 13.96 Example 2 l Ethyl l, 4 dihydro 5 2 hydroxypropoxy 4 oxo 8 propylquinoline 2 carboxylic acid a N Ethyl N 5 methoxy 2 propylphenyl acetamide A solution of N 5 methoxy 2 propylphenyl acetamide 5.0g in dry N,N dimethylformamide l0ml was added dropwise to a stirred suspension of ether washed 50 sodium hydride in oil 1.28g in dry N,N dimethyl formamide under nitrogen. The reaction mixture was stirred for lh, cooled in ice and a solution 6f bromoethane 2ml in dry N,N dimethylformamide lOml added dropwise.The cooling bath was removed and the reaction stirred at room temperature for 2h, poured into ice and dilute hydrochloric acid and extracted with ether which was washed with water 4x50ml and dried over magnesium sulphate. The solvent was evaporated to give 5.0g of the product as a pale yellow oil. The structure was confirmed by nmr and ms.b 3 Ethylamino 4 propylphenol The product of step a 17g was heated under reflux in 70 w w sulphuric acid 170ml for lh. The mixture was cooled, poured onto ice and basified to pH8 with ammonia solution 0.88 specific gravity . The product was extracted with ethyl acetate, washed with water and dried over magnesium sulphate. The solvent was evaporated to give 11.7g of the sub title compound as a red oil. The structure was confirmed by nmr and ms.c Methyl l ethyl 1,4 dihydro s Eydroxy 4 oxo 8 propy guinoline 2 carboxylate A solution of the product of step b 12.6g and dimethyl acetylenedicarboxylate 9.5ml in ethanol 50ml were heated under reflux for lh. The reaction mixture was cooled, poured into water and extracted with ether which was washed with water and dried. The solvent was evaporated to give 21.5g of dimethyl N ethyl N 5 hydroxy 2 propylphenyl 2 aminobutene l, 4 dioate as a viscous oil. The structure was confirmed by nmr and ms. This product and polyphosphoric acid l00ml were heated on a steambath with stirring for 10 min.The reaction mixture was poured onto a mixture of ethyl acetate and ice water, the organic layer was separated, washed with water and dried. The solvent was evaporated and the residue treated with ether and filtered. The filtrate was evaporated and eluted down a silica gel column using ether petroleum ether 4 6 as eluant initially followed by ether petroleum ether 4 1 to give 6.4g of the required sub title product as an orange coloured oil. The structure was cofirmed by nmr and ms.d Methyl I ethyl 1,4 dihydro 4 oxo 8 propyl 5 2 propynyloxy quinoline 2 carboxylate The hydroxyquinoline from step c 6.37g and anhydrous potassium carbonate 6.1g were stirred in dry dimethylformamide, lOOml and treated with a solution of 80 propargyl bromide in toluene 7.5ml . The reaction mixture was stirred for 3 days, poured into water, and extracted with ether which was washed with water 3xlOOml then brine lxlOOml and dried. The solvent was evaporated to leave 6.9g of the sub title product as a viscous oil which solidified on standing. The structure was confirmed by nmr and ms.e Methyl l ethyl l, 4 dihydro 4 oxo 5 2 oxo propyloxy 8 propylguinoline 2 carboxylate The propargyl ether from step d 6.9g , p toluenesulphonic acid 0.86g in water 8ml , and mercuric acetate 0.48g in ethanol 200ml were heated and stirred under reflux for 0.75h. The reaction mixture was cooled, poured into water and extracted with ethyl acetate which was washed with water and dried. The solvent was evaporated, the residue treated with ether, filtered and the filtrate evaporated. The residue was triturated with petroleum ether bp 30 400 to give 6.19 of the sub title product as a yellow brown solid. A recrystallisation from cyclohexane gave the sub title product as a yellow crystalline solid mp 74 760. Elemental analysis Found C, 66.06, , 6.66, N, 4 058 ClgH23NO5 Reqd C, 66.1, H, 6.67, N, 4.06 f Methyl 1 ethyl l,4 dihydro 5 2 hydroxypropyloxy 4 oxo 8 propylquinoline 2 carboxYlate. A solution of the product of step e 5.0g in ethanol 350ml and glacial acetic acid 1.76ml was treated portionwise with sodium borohydride 1.04g with stirring. The reaction mixture was stirred for 0.25h, poured into water, and extracted with ether, which was washed with water and dried. The solvent was evaporated and the residue eluted down a silica gel column using ethyl acetate as eluant to give 3.7g of the sub title product as a yellow brown oil. The structure was confirmed by nmr and ms.g Sodium l ethyl 1,4 dihydro 5 2 hydroxypropyloxy 4 oxo 8 propylquinoline 2 carboxylate A solution of the product of step f 3.53g in methanol 50ml was heated under reflux with the slow addition of N sodium hydroxide solution 10.16ml . The reaction mixture was evaporated until almost dry and treated with acetone to give a sticky solid. The supernatant was decanted and the residue dissolved in water and freeze dried to give 2.63g of the sub title product as a light brown powder. Elemental Analysis Found C, 57.75, H, 6.39, N, 3.64 C18H22NaNO5 4.858 water Reqd C, 57.85, H, 5.9 6.43,N, 3.75 Example 3 l,4 Dihydro 5 2 hydroxypropoxv 4 oxo 8 propylquinoline 2 carboxylic acid a N 2 l Oxopropyl 5 methoxyphenyl acetamide N 3 Methoxyphenylacetamide 82.5g and propionyl chloride 92.5g were dissolved in dichloroethane 1 litre stirred in an ice water bath and treated portionwise with anhydrous ferric chloride 162.5g over lh. The mixture was allowed to warm to room temperature and stirred at ambient for 2h, poured into water and stirred rapidly. The organic layer was separated, washed with water 3x100ml and dried over sodium sulphate.The solvent was evaporated to give a brown oil which was repeatedly extracted with petroleum ether bp 6o80O . The extracts were concentrated to give 34.5g of sub title product as white needles mp 81 84 . The structure was confirmed by nmr and ms.b N 5 methoxy 2 propylpbenyl acetamide The product of step a 2.2g was dissolved in ethanol 80ml , concentrated hydrochloric acid 3 drops added and the solution hydrogenated at atmospheric pressure in the presence of 10 palladium on charcoal 0.4g until hydrogen uptake had ceased. The catalyst was filtered off and the filtrate evaporated to give white solid which was recrystallised from cyclohexane to give 1.4g of the sub title product as off white needles mp 112 113.5 C. Elemental analysis Found C, 69.55. H, 8.15, N, 6.81 C12H17NO2 Reqd C, 69.53, H, 8.27, N, 6.76 c 5 Methoxy 2 propylbenzeneamine The amide of step b 6.7g was heated under reflux in methanol 80ml , concentrated hydrochloric acid 30ml and water 30ml for 2h. The reaction mixture was poured onto ice and basified with ammonia solution 0.88 specific gravity . The product was extracted into ether, washed with water and dried over magnesium sulphate. The solvent was evaporated to give 5.0g of the sub title product as a pale yellow oil. The structure was confirmed by nmr and ms.d Methyl 1,4 dihydro 5 methoxy 4 oxo 8 propylquinoline 2 carboxylate The amine of step c 30.5g and dimethyl acetylenedicarboxylate 25ml were heated under reflux in ethanol 500ml for 2h. The reaction mixture was evaporated to dryness to give 59.2g of dimethyl N 5 methoxy 2 propylphenyl 2 aminobutene 1,4 dioate as an oil. The oil 59.2g was added to diphenyl ether 500ml at reflux. The reaction mixture was heated under reflux for 10 min, cooled, poured into 60 80 petroleum ether and the precipitated product collected by filtration, washed well with petroleum ether and dried to give 35.5g of the product as a light brown solid. A recrystallisation from methanol gave a light brown crystalline sub title product, mp 122 123 0C. Elemental analysis Found C, 65.39, H, 6.18, N, 5.07 C15Hl7NO4 Reqd C, 65.5, H, 6.18, N, 5.09 e Methyl 1, 4 dihydro 5 hydroxy 4 oxo 8 propylquinoline 2 car boxylate The methyl ether from step d 8.0g in dry dichloromethane 300ml was treated with a one molar solution of boron trichloride in dry dichloromethane 88ml at 70 with stirring. The reaction mixture was allowed to warm to room temperature during lh, poured onto ice water, stirred for lh and extracted with ether, which was washed with water and dried over magnesium sulphate.The solvent was evaporated and the residue heated under reflux in methanol 300ml which had been saturated with hydrogen chloride gas for 24 hours. The reaction mixture was poured into water, and extracted with ether which was washed with water and dried. The solvent was evaporated and the residue dissolved in ethyl acetate, silica gel lOOg added and the solvent evaporated. The product was obtained by eluting down a silica gel column using ether as eluant to give 3.2g of the sub title product asa yellow solid mp 90 920. Elemental analysis Found C, 63.76, H, 5.71, N, 5.17 C14Hl5NO4 Reqd C, 64.4, H, 5.75, N, 5.23 f Methyl 8 propyl 4 , 5 di 2 propynyloxy quinoline 2 carboxylate The hydroxyquinoline of step e 1.5g , anhydrous potassium carbonate 3.16g and 80 propargyl bromide in toluene 2.lml were stirred in dry dimethylformamide 100ml for 4 days. The reaction mixture was poured into water, extracted with ethyl acetate, washed with water 4x and dried over magnesium sulphate. The solvent was evaporated to give l.6g of the sub title product. A recrystallisation from methanol gave fluffy cream needles mp 136 137 . Elemental analysis Found C, 71.46, H, 5.81, N, 4.2 C20H19N04 Reqd C, 71.2, H, 5.64, N, 4.15 g Methyl 4 methoxy 8 propyl 5 2 propynyloxy quinoline 2 car boxylate Methanol 500ml was saturated with hydrogen chloride gas, treated with the product of step f 14g and heated under reflux for 3 hours. The reaction mixture was concentrated to low volume, diluted with ether, washed with water, aqueous sodium bicarbonate solution then water again and dried over magnesium sulphate.The solvent was evaporated to give a mixture of the required product and methyl l,4 dihydro 4 oxo 8 propyl 5 2 propynyloxy quinoline 2 carboxylate. This mixture was dissolved in dry dimethylformamide 150ml treated with anhydrous potassium carbonate 6.0g and methyl iodide 3.0ml , and stirred for 1 hour. The reaction mixture was poured into water, extracted with ethyl acetate, which was then washed with water and dried. The solvent was evaporated and the residue recrystallised from cyclohexane to give 10.69 of the required sub title product as a cream coloured solid mp 118 120 . Elemental analysis Found C, 68.98, H, 6.15, N, 4.42 C18El9NO4 Reqd C, 69.0, H, 6.07, N, 4.47 h Methyl 4 methoxy 5 2 oxopropyloxy 8 propylguinoline 2 car boxylate The propargyl ether of step g 4.75g, 0.0152mol , p toluenesulphonic acid 0.6g in water 7.lml and mercuric acetate 0.34g in ethanol lOOml were heated under reflux with stirring for 40 min. The reaction mixture was cooled, poured into ethyl acetate and water, the organic layer separated, washed with water and dried over magnesium sulphate. The solvent was evaporated and the residue recrystallised from cyclohexane to give 2.8g of the sub title product. The structure was confirmed by nmr and ms.i Methyl 1,4 dihydro 4 oxo 5 2 oxopropyloxy 8 propy quinoline 2 carboxylate The product of step h 4.56g in methanol 70ml , water 7ml and conc. HC1 0.7ml were heated under reflux for 7.5h. The reaction mixture was poured into dichloromethane, washed with water, aqueous sodium bicarbonate solution, then water again and dried over magnesium sulphate. The solvent was evaporated, the residue triturated with ether, collected by filtration, washed with ether and dried to give 3.2g of the required sub title product.A recrystallisation from methanol gave brown needles mp 168 1690 Elemental analysis Found C, 64.16, H, 5.95, N, 4.268 C17HlgNO5 Reqd C, 64.4, H, 6.0, N, 4.42 j Methyl 1, 4 dihydro 5 2 hydroxypropyloxy 4 oxo 8 propylquinoline 2 carboxylate The product of step i 2.83g was dissolved in dimethylformamide 60ml with slight warming and treated with glacial acetic acid l.lml followed by the slow addition of sodium borohydride 0.64g with stirring. The reaction mixture was then stirred for lh, poured into water, extracted with ethyl acetate, washed with water 4x and dried.The solvent was evaporated and the residue eluted down a silica gel column using ethyl acetate petroleum ether 4 1 as eluant to give 2.22g of the sub title compound as a yellow gum which solidified on standing mp 78 810. Elemental analysis Found C, 63.81, II, 6.61, N, 4.23 C17H21NO5 Reqd C, 63.9, H, 6.58, N, 4.39 k Sodium l,4 dihydro 5 2 hydroxypropyloxy 4 oxo 8 propylquinoline 2 carboxylate The quinolone of step j 1.906g in methanol 40ml was heated under reflux with stirring with the slow addition of N sodium hydroxide solution 5.98ml . The reaction mixture was then heated and stirred under reflux for 0.5h, allowed to cool to room temperature and concentrated to dryness. The residue was dissolved in water, filtered and the filtrate freeze dried to give 1.745g of the title sodium salt.Elemental analysis Found C, 53.98, H, 5.26, N, 3.88 C16E18NNaO5 8.04 water Reqd C, 53.98, H, 5.06 5.94, N, 3.94 Gravimetric analysis showed 8.04 weight loss.Example 4 5 2 Hydroxypropoxy 4 oxo 6 , 8 dipropyl 4H l benzopyran 2 carboxylic acid a 2 Acetyl 4 , 6 dipropyl resorcinol A mixture of 2 acetyl 4,6 diallyl resorcinol 30g and 5 palladium on charcoal, 0.25g in ethanol, 150ml was shaken in 3 atmospheres pressure of hydrogen for 2 hours. Normal atmosphere was restored and catalyst was filtered off and destroyed. The filtrate was evaporated to leave sub title material as a green solid 930g , m.p 50 , which was satisfactory on nuclear magnetic resonance spectroscopy. b 2 Hydroxy 6 2 hydroxypropoxy 3, 5 dipropylacetophenone A mixture of the product of step a 30g with propylene oxide 15ml and 5ml of a 40 solution of benzyltri methyl ammonium hydroxide in water, was dissolved in dioxan 250ml , sealed in a glass vessel and then heated in a steam bath for 40 hours. The mixture was cooled and then solvent was evaporated off. The residue was dissolved in ether 150ml and the solution was washed with water, then with 1 sodium hydroxide solution, again with water, dried MgSO4 , filtered and evaporated to leave the sub title material as a red oil, 20.5g .Nuclear magnetic resonance supported the structure proposed. c 5 2 Hydroxopropoxy 4 oxo 6,8 dipropyl 4E lbenzopYran 2 carboxylic acid To a stirred solution of sodium ethoxide, prepared by dissolving sodium 8g in ethanol 250ml , was added a solution of the product of step b 20.5g and diethyl oxalate, 25g in ethanol 100ml . The mixture was stirred and kept under reflux for 5 hours, then it was poured into a stirred mixture of concentrated hydrochloric acid, 40ml , water 200ml and chloroform 200ml . The chloroform layer was isolated and combined with a further chloroform wash of the aqueous layer The total chloroform solution was washed with water, 2 x 200ml , dried MgS04 filtered and evaporated.The residual oil was dissolved in ethanol, looms and treated with conc. EC1, 2ml . This mixture was kept under reflux for 1 hour after which the solvent was removed. The residue was treated with sodium bicarbonate, 8g methanol, 50ml and water 150ml and this mixture was kept under reflux for 1 hour, evaporated and then extracted into water. The aqueous solution was washed with ether, filtered and then acidified with 5N hydrochloric acid. Precipitated material solidified upon standing and was subsequently dissolved in chloroform. The solution was washed with water and then evaporated to leave the title material, 8.6g , m.p. 135 7 . Analysis Found C, 65.8 H, 7.0 C19H2406 requires C, 65.6 H, 6.94 d Sodium 5 2 hydroxypropoxy 4 oxo 6,8 dipropyl 4H l benzopyran 2 carboxylate The product of step c 8.2g was dissolved in a solution of sodium bicarbonate, 2.lg in water 40ml . The solution was filtered, evaporated to near dryness and then diluted with acetone. Crystallisation occurred. The crystals were filtered off, crushed, and dried in vacuo at 80 for 2 hours to leave. the sub titl e material as a white powder, 7.7g . Structural evidence was provided by nuclear magnetic resonance spectroscopy.Analysis Found C, 54.05 H, 6.6 ClgH23NaO6.3H20 requires C, 53.8 H, 6.8 Example 5 5 2 Hydroxypropoxy 7 methyl 4 oxo 8 propyl 4H 1 benzopyran 2 carboxylic acid a 1 2 Hydroxy 4 methyl 6 2 propenyloxy phenyl ethanone 1 2, 6 Dihydroxy 4 methylphenyl ethanone 33.7g , K2CO3, 35g , allyl bromide 21ml and dimethylformamide 400ml were stirred together for 18 hours and poured into water. The precipitated sub title compound was collected, dried and recrystallised from 60 80 petroleum ether. mp 8486O. b 1 2,6 Di hydroxy 4 methyl 3 2 propenyl phenyl ethanone The product of step a 26g was heated in tetralin 52ml at 165 170 for 2 hours. After cooling the precipitated sub title compound was collected, washed with petroleum ether and dried. mp 104 1060. c 1 2 Hydroxy 6 2 hydroxypropoxy 4 methyl 3 t2 propenyllphenyl ethanone The product of step b 23.5g , propylene oxide 44ml , tetraethyl ammonium bromide 0.9g and dioxan 30ml were heated at 1000 in a sealed container for 2.5 hours, then cooled and poured into water. Chloroform extraction, and washing with water followed by drying and evaporation afforded the sub title compound as an oil 30g MS M 264 By191. d 1 2 Hydroxy 6 t2 hydroxypropoxyl 4 methol 3 proPYl phenyl ethanone The product of step c 30g was hydrogenated over 5 Pd C lg at 1 atmosphere H2 pressure in ethanol 200ml until hydrogen uptake ceased. The catalyst was filtered off, and solvent was evaporated. The residue was triturated with petroleum ether, then recrystallised from 40 60 petroleum ether to afford the sub title compound tlS.6g mp 76 77 . e Sodium 5 2 hydroxypropoxy 7 methyl 4 oxo 8 propyl 4H l kenzopyran 2 carboxylate Sodium hydride 2.8g was added to a suspension of the product of step d 15.6g and diethyl oxalate 17.2g in 60 80 petroleum ether 200ml . Gentle warming resulted in brisk effervescence and when this subsided the mixture was refluxed for 15 minutes. On cooling ethanol 65ml and conc. HC1 16ml were added. The mixture was heated on a steam bath for 10 minutes, then cooled, evaporated and extracted into chloroform. The organic solution was washed with water, dried and evaporated to afford the chromone ester as an oil 20g . The oil 20g was dissolved in methanol SOml together with sodium bicarbonate 7.6g and water 90ml and refluxed for 2 hours. The solution was cooled, washed with chloroform, then acidified and extracted intoCHC13. The extract was washed with water, dried and evaporated. The resulting acid was dissolved in a solution of sodium bicarbonate 50g in water 100ml with heating. The solution was filtered, cooled and diluted with acetone. The resulting precipitate was collected and dried to afford the title compound 11.2g mp 3000.Example 6 6, 8 Diethyl 5 2 hydroxypropoxy 4 oxo 4H 1 benzopyran 2 carboxylic acid a 1 3,5 Diethyl 2 hydroxy 6 2 hydroxypropoxy phenyl ethanone 1 3,5 Diethyl 2,6 dihydroxy phenyl ethanone 16.9g , propylene oxide 15ml , benzyltrimethylammonium hydroxide 20 drops and dioxan 30ml were heated together in a sealed system at 1000 for 21 hours. Volatile materials were then evaporated off and the residue was extracted into chloroform, which was washed with water, dried and evaporated to leave an orange oil 20.lg . NMR consistent with the desired structure.b 6, 8 Diethyl 5 2 hydroxypropoxy 4 oxo 4H l benzopyran 2 carboxylic acid To a solution of sodium 11.5g in ethanol 450ml was added the product of step a 20g and diethyl oxalate 29g dissolved in ethanol 50ml . After refluxing for 15 hours the cooled solution was poured into a mixture of conc. HC1 Sml and left for 10 minutes. The resulting mixture was evaporated and the residue was refluxed with methanol 40ml , water l00ml and sodium bicarbonate 10g for 1 hour. Methanol was evaporated and the aqueous residue was diluted with a little water, filtered and acidified to afford an oil.Repeated trituration with ether afforded the title compound 3.5g mp 167 1690, c Sodium 6, 8 diethyl 5 2 hydroxypropoxy 4 oxo 4H 1 benzopyran 2 carboxylate The product of step b 3.2g and sodium bicarbonate 0.84g were dissolved in water lOOml , filtered and the solution was lyophilised to afford the title compound 3.2g mp 3000.Example 7 5 2, 3 Dihydroxy n propoxy 4 oxo 8 n propyl 4H l benzopyran 2 carboxylic acid The sodium salt of 5 2 hydroxy n propoxy 4 oxo 8 n propyl 4H l benzopyran 2 carboxylic acid was prepared as a 50 suspension in isotonic saline.Animals Male Cob Wistar rats weight approximately 350g were obtained from Charles River Manston, Kent, UK . Animal dosing and urine collection Six rats were dosed twice daily with dosing solution 5ml for 6 days. The daily dose was approximately kg l l 14g kg 1 day . The urine from each rat was collected daily and pooled.Extraction of urine The pooled urine was acidified to pHl by the addition of concentrated HC1. The acidified urine was then extracted twice with two volumes of diethyl ether. The diethyl ether extract was evaporated to dryness under reduced pressure at 300. The residue was redissolved in methanol lOml .High performance liquid chromatography Aliquots 100 ul of the extract or subsequently partially purified fractions were injected onto aSpherisorb 50DS 25 cm x 0.8mm id column. The column was eluted with a mobile phase consisting of 35 methanol 65 water containing ammonium acetate 5 at a rate of 4ml min 1 by pump. The column eluate was monitored at 350 nm by a W detector.Extraction Combined fractions of eluate were concentrated under reduced pressure at 450 to remove methanol. The concentrate was then acidified to pH 1 with concentrated HC1 and extracted twice with two volumes of diethyl ether. The ether was removed by evaporation under reduced pressure. The samples were then analysed and unchanged starting material together with the title compound were identified.Example 8 5 2,3 Dihydroxy n propoxy 4 oxo 8 n propyl 4R 1 benzopyran 2 carboxylic acid a Ethyl 4 oxo 5 2 propenyloxy 8 propl 4H li benzopyran 2 carboxylate A stirred solution of sodium metal, 47.lg , in dry ethanol, l000m1 , was treated dropwise with a solution of diethyl oxalate, 150.3g, 140ml , and l 2 hydroxy 6 2 propenylox.y 3 propylphenyl ethanone, 95g , in dry ethanol, 300ml . The resulting mixture was heated at reflux for 3 hours, then left to cool overnight and poured into a mixture of conc. HC1 250ml , water, l000ml , and chloroform, 1000ml . The organic layer was isolated, washed with water, 4 x l000ml , dried MgSO4 , filtered and evaporated to a red oil. This was heated under reflux for 1 hour in ethanol C.HCl and the resulting solution was left overnight in a refrigerator. The resulting crystalline solid was filtered off and dried to constant weight, 68g . A portion log , was dissolved in chloroform and the solution was washed with NaRC03 solution, water, dried MgSO4 , filtered and evaporated. The residue was recrystallised from ethanol and dried in vacuo at 400 for 5 hours, leaving a yellow solid, 8.0g , mp 85 860. Elemental analysis found C,68.5 H,6.4 C18E2005 Requires C,68.34 H,6.378 b Ethyl 5 2, 3 Dihydroxy n propoxy 4 oxo 8 n propyl 4H l benzopyran 2 carboxylate 316Mg of the product of step a lmmol in 5.5ml of a 63 solution of hydrogen peroxide in t butanol lOml and 300 pl of a 0.5 solution of osmium tetroxide in t butanol were stirred at room temperature for three hours. Thin layer chromatography monitoring in ether acetone 9 1 revealed no further increase in product after three hours.The t butanol was evaporated off under pressure and the residue taken up in a small volume of HC13 CH3OH and applied to two preparative thin later chromatography plates which were developed inCHC13 CH3OH 9 1 , the band due to the diol removed, and the silica eluted with CHC13 CH30H 1 1 . The.organic solvent was removed under reduced pressure to give 262mg of slightly impure product which was recrystallised from aq. ethanol to give 163mg of the sub title compound whose structure was confirmed by mass spectroscopy c 5 2, 3 Dihydroxy n propoxy 4 oxo 8 n propyl 4H l benzopyran a car boxylic acid 40Mg of the product of step b 0.ll4mmol and 9.6mg of Nay003 0.114 mmol in 2mls of methanol were heated together at 700.The reaction was monitored by thin layer chromatography in chloroform methanol 3xlOml , acidified and extracted with CHC13 isopropanol 3xlOmls . The organic solvent was removed under reduced pressure and trituration of the resulting gum with ether gave a yellow solid which was dried under vacuum to yield 12.6mg of the title compound whose structure was confirmed by NMR spectroscopy.Example 9 5 2, 3 Dihydroxypropoxy 4 oxo 8 propyl 4HElJ benzopyran 2 carboxylic acid a Ethyl 5 oxiranylmethoxy 4 oxo 8 propyl 4HtllbenzoFuran 2 carboxylate A solution of ethyl 4 oxo 5 2 propenyloxy 8 propyl 4Htl benzopyran 2 carboxylate, 16.0g , in dry dichloromethane, 175ml , was stirred and cooled in an ice bath, then treated portionwise over 15 minutes with 3 chloroperoxybenzoic acid, 95 purity, 13.8g . The mixture was maintained at ice temperature for a further 2 hours, allowed to reach room temperature and then stirred for 90 hours.Excess oxidant was destroyed by addition of sodium bisulphite solution and the organic layer was washed with NaHC03 solution, water, and then dried and evaporated. The residue was twice crushed under ether and filtered off, leaving the sub title compound as a yellow solid 5.95g . The structure was confirmed by NMR spectroscopy.b Ethyl 5 2, 3 dihydroxypropoxy 4 oxo 8 propyl 4HElJ benzopyran 2 carboxylate A solution of the epoxide from step a , 3g , was dissolved in acetone, 100ml , and treated at room temperature with 3M H2S04, 1Sml . The resulting solution was left to stand for 1.5 hours and then evaporated to dryness. The residue was diluted with water and extracted into ethyl acetate. The extracts were washed with water, brine, water again, then dried, MgSO4 , filtered and evaporated. The residue, 1.8g , was chromatographed on silica gel, 90g, 70 230 mesh , eluting in order with CH2C12 ethylacetate 1 1, neat ethyl acetate, and ethyl acetateethanol 97 3, which gave the required product.The fractions were evaporated and the residue was triturated with ether, leaving a yellow solid, l.Og mp 141 14 Elemental analysis found C,62.08 H,6.45 C18H2207 requires C,61.7 ,6.3 c 5 2,3 Dihydroxypropoxy 4 oxo 8 propyl 4H 1 benzopyran 2 carboxylic acidA solution of the ethyl ester from step b 0.87g , in ethanol, 60ml , was treated dropwise at reflux with 2MNaOH solution, 1.25ml . After 10 minutes the mixture was evaporated and the residue was dissolved in water. This solution was washed with ether, warmed under vacuum and then filtered. The filtrate was acidified and the precipitate was extracted into ethyl acetate.The extracts were dried, MgSO4 , filtered and evaporated, the residue was crushed under ether and filtered off, leaving the sub title compound as a pale yellow solid, 0.65g mp 143 145 . d Sodium 5 2,3 dihydr oxYpropoxY 4 oxo 8 proPyl 4S benzopyran 2 carboxylate A solution of the carboxylic acid from step c 0.49g , in ethanol, 25ml , was treated dropwise at room temperature with 0.5M NaOH solution, 3.04ml . The solution was evaporated and the residue was dissolved in sterile water, filtered and the filtrate freeze dried overnight, giving the required salt as a yellow solid 0.499 . Analytical HPLC reports 99.8 purity.Thermal gravimetric analysis showed 5.5 wt. loss at 1500. Elemental analysis found C,52.42 H,5.29C16H17Na07 5.5 H20 requires C,52.73 H,5.33 Example 10 5 2 Hydroxypropoxy 4 oxo 8 phenylmethyl 4H 1 benzopyran 2 carboxylic acid a 1 2, 6 Dihydroxy 3 phenylmethylphenyl ethanone 2,6 Dihydroxy acetophenone 38g , chloroform 500ml , 60 80 petroleum ether 500ml and orthophosphoric acid 200g were refluxed and stirred while a solution of benzyl alcohol 53.25g in chloroform lOOml was added over 1 hour. When addition was complete refluxing was continued for 3 hours. The mixture was then cooled and the organic phase was decanted, washed with water and dried.Evaporation afforded a gum which was triturated with petroleum ether and recrystallised from CCl4 to afford the sb title compound 39.5g mp 117 1190. b 1 2 Hydroxy 6 t2 hydroxypropoxyi 3 phenylmethyl phenyl ethanone The product of step a 18,1g , propylene oxide 6.5g, benzyltrimethylammonium hydroxide 0.75ml and dioxan 75ml were heated in a sealed container at 1000 overnight. After cooling, volatile materials were. removed under vacuum and the residue was dissolved in ether, washed with 1N NaOH, water, dil. HCland water. Drying and evaporation afforded the sub title compound 9.9g. NMR spectrum consistent with the desired structure.c 5 2 Hydroxypropoxy 4 oxo 8 phenylmethyl 4H 1 benzopyran 2 carboxylic acid The product of step b 9.6g was added to a solution of sodium 3.68g in ethanol 500ml , and then diethyl oxalate 11.84g was added. The mixture was refluxed for 1.25 hours, then poured into CHC13 800ml and ail. HC1 lOOml . The organic phase was evaporated, and the residue was treated with conc. H2SO4 lml in ethanol 50ml at room temperature for 15 minutes. Ethanol was evaporated and the oil was dissolved in 1 1 ethanol water 150ml and treated with sodium bicarbonate 30gm . This mixture was refluxed for 1 hour and then the ethanol was evaporated.The aqueous solution was washed with ethyl acetate, acidified and extracted into CHC13. Evaporation gave a gum which was triturated with ether, and recrystallised from ethyl acetate to afford the sub title compound 1.2g mp l702O. c d Sodium 5 2 hydroxypropoxy 4 oxo 8 phenylmethyl 4H 1 benzopyran 2 carboxylate The product of step c 3.54g and sodium bicarbonate 0.84g were heated together in water lOOml until dissolved. The solution was filtered and the solution lyophilised to afford the sub title compound 3.69 mp 300 . Example 11 5 2 Benzoyloxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 carboxylic acid a Ethyl 5 2 benzoyloxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 carboxylate A mixture of ethyl 5 2 hydroxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 carboxylate 5g , dry pyridine, 6ml and benzoyl chloride, 4g in dry 1,2 dichloroethane, 50ml was heated under reflux for 1 hour, and then left at ambient temperature overnight. Volatile components were then evaporated and the residue was triturated with cold dilute hydrochloric acid, washed with water, triturated with cold sodium bicarbonate solution, washed with water and then dried, in vacuo at 500, to leave the sub title material as a tacky, pale orange oil, 5.6g .The proposed structure was supported by NMR studies and by mass spectroscopy.b 5 2 Benzoyloxypropoxy 4 oxo 8 propyl 4E 1 benzopyran 2 carboxylic acid A solution of the product of step a 5.5g in dimethylformamide, 25ml was heated on a steam bath and treated over 15 min with a solution of sodium bicarbonate 3g in water, 40ml . This mixture was heated on a steam bath for a further 1.25 hour, evaporated to low bulk 25g cooled and diluted with water. The resulting mixture was filtered and the filtrate was carefully acidified with dilute hydrochloric acid. A solid was precipitated, which was filtered off, washed with water, and then dissolved in ether. The ethereal solution was dried Na2S04 , filtered and then diluted with 40 60 petroleum ether.Crystallization occurred and gave the sub title material as a pale cream powder 1.95g , mp 108 100. Satisfactory nuclear magnetic resonance and mass spectroscopic data were obtained.c Sodium 5 2 benzoyloxypropoxy 4 oxo 8 propyl 4H l benzopyran 2 carboxylate A mixture of the product of step b 1.85g and sodium bicarbonate, 0.4g in water 8ml was stirred to give a clear solution, which was flooded with acetone.The precipitated solid was filtered off and discarded and the filtrate was evaporated to dryness. The residue was re dissolved in dry acetone and the solution was diluted with dry ether. Crystallization occurred and gave sub title material as an off white powder 1.6g . The proposed structure was supported by nuclear magnetic resonance and mass spectroscopic data. Analysis Found C,62.92 H,4.80 C23H21NaO7 1.5 H20 Requires C,62.9 H,4,78 4.92Example 12 Butanedioic acid, mono 2 ethoxycarbonyl 4 oxo 8 propyl4H l benzopyran 5 yloxy prop 2 yl ester a Butanedioic acid mono 2 ethoxycarbonyl 4 oxo 8 propyl 4H l benzopyran 5 yloxy prop 2 yl ester A solution of ethyl 5 2 hydroxypropoxy 4 oxo 8propyl 4H l benzopyran 2 carboxylate, 9.8g in pyridine l0Oml was treated with succinic anhydride, 5g and the resulting solution was heated on a steam bath for 17hr. Most of the pyridine was evaporated off and the concentrate was exhaustively triturated with cold N HCl, then with water and dried to leave sub title material as an off white powder, 13g , m.p. 146 90. SatisfactoryN.M.R. spectra were obtained.b Butanedjoic acid, mono 2 ethoxycarbonyl 4 oxo 8 propyl 4H l benzopyran 5 yloxy prop 2 yl ester mono sodium salt The product of step a l.Sg was carefully dissolved in a solution of sodium bicarbonate, 0.3g in water 15ml . The solution was filtered and freeze dried to leave the sub title material as a straw coloured, deliquescent solid, 1.2g . Analysis Found C, 55.37 H, 7.22C22H25NaO9 1.25H20 requires C,55.17,H, 5.53 Example 13 .5 2 Hydroxypropoxy 4 oxo 8 propyl 4H l thiabenzopyran 2 carboxylic acid a Ethyl 4 oxo 5 propargyloxy 8 propyl 4H l thiabenzopyran 2 carboxylate. A mixture of 80 w w propargyl bromide in toluene 20g and ethyl 5 hydroxy 4 oxo 8 propyl 4H thiabenzopyran2 carboxylate, 14.6g in dry N,N dimethylformamide, 75ml was stirred and cautiously treated with 50 w w sodium hydride in oil. The mixture was heated on a steam bath for 18hr. Volatile materials were removed and the residue was extracted with ether. This extract was filtered, evaporated, and the residue was extracted with boiling 40 60 petroleum ether. Material remaining undissolved was subsequently crytallised from a 60 80 petroleum ether ethyl acetate mixture to give sub title material as brown crystals, 5g , m.p.95 80. a Ethyl 5 acetonyloxy 4 oxo 8 propyl 4H l thiabenzopYran 2 carboxylate A mixture of the product of step a 4.4g , with 40 boron trifluoride acetic acid complex, 0.39 and red mercuric oxide, 0.04g in glacial acetic acid, 40ml , was heated on a steam bath for 1 hr. Most of the solvent was evaporated off and the contentrate was diluted with water. The aqueous phase was discarded and the organic deposit was extracted into ethyl acetate. This extract was diluted with 60 80 petroleum ether and filtered.The filtrate, upon further dilution with 60 80 petroleum ether, deposited an oil, which upon standing solidified to leave the sub title material as a brown powder, 3.25g m.p. 88 98 . c Ethyl 5 2 hydroxypropoxy 4 oxo 8 propyl 4H l thiabenzopyran 2 carboxylate A solution of the product of step b 2.15g and glacial acetic acid, 0.8g in ethanol, 40ml was stirred and treated over a few minutes with sodium borohydride, 0.4g . Stirring was continued for 10 min. and the mixture was then allowed to stand for 10 min. Volatile materials were removed and the residue was partitioned between ether and water. The ethereal layer was isolated and evaporated and the residue was crystallised, from an ethyl acetate 60 80 petroleum ether mixture, to give the sub title material as orange crystals, 1.2g , m.p. 102 7 . d Sodium 5 2 hydroxypropoxy 4 oxo 8 propyl l thiabenzopyran 2 carboxylate A mixture of the product of step c 1.2g , sodium bicarbonate, 0.6g , water, 20ml and methanol, 2Oml was heated under reflux for 40 min. andthen most of the solvent was removed. The concentrate was diluted with water, and then evaporated to low bulk. This concentrate was diluted with acetone and excess inorganic material was filtered off. The filtrate was evaporated to near dryness and then treated with anhydrous acetone.Crystallization occurred yielding the sub title material as a fawn powder, 0.869 Analysis Found C, 53.56 H, 5.21 C16H17NaO55.0. 75H2O requires C,53.7,H, 5.17 Example 14 8 1, 1 Dimethylethyl 5 2 hydroxypropoxy 4 oxo 4HtlZbenzopyran 2 carboxylic acid a 2,6 Dihydroxy 3 1,1 dimethylethyl phenslethanone A stirred mixture of 2,6 dihydroxyphenylethanone, 30.4g , orthophosphoric acid, 160g , chloroform, 400ml , and petroleum ether, 400ml, bp 60 80 was heated under. reflux and treated dropwise over 1.25h with a solution of t butanol, 29.6m1 , in chloroform, 80ml .The resulting mixture was heated under reflux for a further 4h, evaporated to lower bulk, 250ml , and cooled to room temperature. Chloroform 1.5 1 , was added and the supernatant yellow solution was decanted from H3PO4. The organic solution was washed with brine, dried, MgS04 , filtered and evaporated to near dryness. Petroleum ether, 1.5 1 bp40 600 was added, the solid was filtered off, washed with petroleum ether and dried, giving the required material as a yellow crystalline solid, 23g . Recrystallisation from ether petroleum ether bp40 600 gave the sub title compound, mp 187 9 . Structure was confirmed by NMR.b 3 1,1 Dimethylethyl 2 hydroxy 6 2 hydroxypropOxy phenylethanone A solution of the product from step a , 31.5g , propylene oxide, 13.05g and benzyltrimethyl ammonium hydroxide, 2.5ml of a 40 solution , in 1,4 dioxan 125ml , was heated to 100 in a sealed vessel for 16hr. The solvent was removed and the residue was dissolved in ether. This solution was washed with 1M NaOH solution, water, dil. HCl, water again, dried, MgSO4 , filtered and evaporated to dryness, leaving the sub title compound as a green oil, 36.0g .c Ethyl 8 1,1 dimethylethyl 5 2 hydroxypropoxyE 4 oxo 4Htllbenzopyran 2 carboxylate A stirred solution of sodium metal, 15.5g , in ethanol, 500ml , was treated with the product from step b , 36.0g and then with diethyl oxalate, 49.0g . This mixture was heated at reflux for 45 min., cooled and poured into chloroform, 1500ml , containing excess conc.HC1 and water. The organic layer was isolated, evaporated, and the residue was heated under reflux with ethanol, 250ml and conc. HCl, 10 drops , for 45min.The ethanol was evaporated off and the residue was triturated with ether. Insoluble material was isolated by filtration and dried in vacuo, leaving a pale yellow solid, 23.9g . This solid was recrystallised from benzene petroleum ether to give material, mp 110 111 . Analysis found C, 65.2 ,7.1 C19H2406 required C, 65.5 H,6.94 d 8 1, 1 Dimethylethyl 5 2 hydroxypropoxy 4 oxo 4H tllbenzoporan 2 carboxYlic acid A mixture of the ester from step c , 17.6g , in methanol, 100ml , was treated with a solution of NaHC03, 17.6g , in water, 500ml . The resulting cloudy mixture was heated under reflux for 1.5h and then the methanol was evaporated off. The aqueous solution was filtered and acidified to pH 1 with conc. HC1. After standing the supernatant solution was decanted off and the residual gum was rinsed with clean water and then triturated with petroleum ether. The resulting solid was filtered off, dried, 15g , and crystallised from aqueous acetone to give the required acid, 14.09 , mp 93 95 . Analysis found C, 63.45 H, 6.45 C17H2006 requires C, 63.74 H, 6.29 e Sodium 8 1,1 dimethylethyl 5 2 hydroxypropoxy 4 oxo 4H 1 benzopyran 2 carboxylate The acid from step d , 10.7g , was added to a solution of NaHCO3, 2.73g , in water 50ml . The resulting solution was filtered, freeze dried and the product was dried in vacuo, 10.4g . Analysis found C, 57.6 H, 5.8 C17HlgNaO6.3.4 water requires C, 57.6 H, 5.8 .Example 15 8 2 Hydroxypropoxy 9 oxo 5 propyl 1E,9E benzopyrano r2,3 d v triazole a 9 oXo 8 2 oxopropoxy 5 propYl lE,9E benzopyrano 2 ,3 dJ v triazole 8 Hydroxy 9 oxo 5 propyl 1H,9H benzopyrano 2,3 d v triazole 24.5g , potassium carbonate 27.6g , dry dimethylformamide 500ml and chloroacetone 9.2g were stirred together for 4 days at room termpature under nitrogen. The mixture was diluted with water 5L and the pH was adjusted to 7 with acetic acid. The aqueous solution was extracted with ethyl acetate which was then evaporated. The residue was separated by high performance liquid chromatography to afford the sub title compound 0.2g . Structure was supported by m.s. b Sodium salt of 8 2 hydroxypropoxy 9 oxo 5 propyl 1H,9H benzopyrano 2,3 d v triazole The product of step a was treated with sodium borohydride O.lg in ethanol 20ml at room termperature for 24hr, then the mixture was acidified with acetic acid and evaporated. The residue was extracted well with ethyl acetate, which was evaporated to afford the hydroxy compound 0.05g . This gummy solid was treated with sodium hydroxide 1.6ml of 0.1N solution at room temperature. After stirring for 30 min the solvent was removed by lyophilisation to afford the title compound 0.58g mp30o0C.